yourstate.us
21 CFR 522.1083

§ 522.1083 Gonadotropin releasing factor analog-diphtheria toxoid conjugate.

United States · 21 CFR — Food and Drugs · Status: effective

Get this as JSONEmbed this
Cite this
Citation
21 CFR 522.1083, § 522.1083 Gonadotropin releasing factor analog-diphtheria toxoid conjugate, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/87458
Permanent ID
ys:prov:87458@1
SHA-256
f58a3da6e51a9195ed4f32d36ff34a018e550779a7c2f3a4f1546769bc45697c

The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.

Full text

(a) Specifications. Each milliliter (mL) of solution contains 0.2 milligrams (mg) gonadotropin releasing factor analog-diphtheria toxoid conjugate. (b) Sponsor. See No. 054771 in § 510.600(c) of this chapter. (c) Conditions of use in swine—(1) Amount. Each intact male pig or gilt should receive two 2-mL (0.4 mg) doses by subcutaneous injection. Administer the first dose no earlier than 9 weeks of age. Administer the second dose at least 4 weeks after the first dose. (2) Indications for use—(i) Intact male pigs intended for slaughter: For the temporary immunological castration (suppression of testicular function) and reduction of boar taint. (ii) Gilts intended for slaughter: For the temporary suppression of estrus. (3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For reduction of boar taint, intact male pigs should be slaughtered no earlier than 3 weeks and no later than 10 weeks after the second dose.

Legislative history

This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.